IXICO plc (GB:IXI) has released an update.
IXICO plc, a precision analytics company specializing in neuroscience insights, has secured a contract worth over £1 million to provide imaging biomarker services for a Phase 3 Parkinsonian disorder trial. The contract, awarded by a top five CRO for a new pharmaceutical client, underlines IXICO’s growing recognition in the drug development industry for its expertise in neurodegenerative disorders. This comes on the heels of another recent contract win for an Alzheimer’s Disease study, showcasing the company’s expanding portfolio.
For further insights into GB:IXI stock, check out TipRanks’ Stock Analysis page.
